Reports Q3 revenue $13.5M, consensus $13.04M. “Market dynamics continue to align in our favor as we maintained strong top-line growth and increased profitability. Our Deep TMS system drove record demand in the third quarter of 2025, with meaningful adoption among both existing and new customers. Looking ahead, we see significant opportunities to extend our leadership through new therapeutic indications, accelerated treatment protocols, and broader market adoption initiatives, including potential strategic collaboration involving complementary technologies such as the at-home solutions offered by Neurolief following our recent investment in that company” said Hadar Levy, BrainsWay’s (BWAY) Chief Executive Officer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BWAY:
- BWAY Earnings this Week: How Will it Perform?
- BrainsWay Secures NIH Grant for Deep TMS Study on Alcohol Use Disorder
- Brainsway announces NIH awarded a grant totaling about $2.5M over 5 years
- Brainsway’s Strategic Investments and Growth Potential Drive Buy Rating with $17 Price Target
- Brainsway’s Deep TMS Study: A New Hope for Alcohol Use Disorder